IL6 and Alzheimer disease: Notably, combination treatment significantly improved cognitive performance, reduced neuroinflammatory cytokine levels (IL-6 and TNF-α), decreased expression of AD-related proteins (APP and MAPT), and restored redox balance, as evidenced by increased SOD activity and reduced MDA content.